INTRODUCTION {#s1}
============

Six classes of neurons and Müller glial cells are generated from a common retinal progenitor cell (RPC) population, following a precise temporal sequence ([@DEV142042C34]). The first differentiated cells in the mouse are retinal ganglion cells (RGCs), followed by horizontal, cone and amacrine cells. Development of rod photoreceptors, bipolar cells and Müller glia extends into the second postnatal week ([@DEV142042C9]).

Transcription factors (TFs) act intrinsically during different stages of retinogenesis. Homeodomain (HD) and basic helix-loop-helix (bHLH) TFs initiate retinal development and maintain RPC ([@DEV142042C43]). Overexpression of seven eye field TFs in *Xenopus* embryos can induce eye-like structures with functional properties ([@DEV142042C49]).

*Atoh7* (also known as *Math5*) is a bHLH TF essential for RPCs to become RGCs ([@DEV142042C7]; [@DEV142042C52]; [@DEV142042C56]). *Brn3b* (*Pou4f2*) genetically downstream of *Atoh7* is required for the terminal differentiation and survival of most RGCs, but not for their initial specification ([@DEV142042C19], [@DEV142042C20]; [@DEV142042C23]; [@DEV142042C54]). *Brn3b* and *Brn3a* (*Pou4f1*) have overlapping yet distinct roles controlling RGC development and function ([@DEV142042C3]). *Isl1*, a LIM-HD TF, under the regulation of ATOH7, defines a distinct but overlapping subpopulation of RGCs with *Brn3b* ([@DEV142042C42]; [@DEV142042C45]). This *Atoh7*-*Brn3b*/*Isl1* pathway determines a population of RGCs, whereas other RGCs rely on the Distal-less homeobox genes *Dlx1* and *Dlx2* for their differentiation and survival ([@DEV142042C13], [@DEV142042C14]).

Retinas from *Dlx1*/*Dlx2*^−/−^ mice have reduced RGCs due to enhanced apoptosis of late-born RGCs ([@DEV142042C13]). DLX1/DLX2-mediated regulation of the *Dlx5/6* intergenic enhancer and brain-derived neurotrophic factor-mediated TrkB signaling may contribute to the differentiation and survival of RGCs, respectively ([@DEV142042C14]; [@DEV142042C57]).

DLX2 and BRN3B are expressed in distinct but partly overlapping regions in the retinal neuroepithelium ([@DEV142042C12]) ([Fig. S1](Fig. S1)). Furthermore, DLX2 and to a lesser extent DLX1, are expressed in cycling as well as postmitotic RPC ([@DEV142042C18]). We hypothesized that *Dlx1* and/or *Dlx2* and *Brn3b* function in parallel intrinsic pathways to determine RGC fate and generated *Dlx1*/*Dlx2*/*Brn3b* triple knockout (TKO) mice. We found almost complete RGC loss with a marked increase in amacrine cells in the ganglion cell layer (GCL). DLX1 and DLX2 were also identified as transcriptional activators of *Brn3b* expression supported by *in utero* retinal electroporation of *Dlx2* and siRNA-mediated knockdown of *Dlx2* in primary embryonic retinal cultures. Taken together, DLX1 and DLX2 are necessary and sufficient for *Brn3b* expression during retinal development.

RESULTS {#s2}
=======

Loss of *Dlx1*/*Dlx2* and *Brn3b* gene function leads to defective RGC specification {#s2a}
------------------------------------------------------------------------------------

In the *Dlx1/Dlx2* DKO there is 33% loss of late-born RGCs at E18.5, whereas *Brn3b* deletion results in a 60-70% reduction of RGCs in the postnatal retina, depending upon the genetic background. However, neither the *Dlx1/Dlx2* DKO nor the *Brn3b* single knockout (SKO) have defects in other retinal cell classes ([@DEV142042C13]; [@DEV142042C19]; [@DEV142042C23]). We hypothesized that the TKO retina would have severe abnormalities in RGC differentiation and survival, with a significantly reduced GCL. *Dlx1/Dlx2/Brn3b* TKO mice die shortly after birth at P0. Unexpectedly, the TKO retina showed only a modestly decreased GCL ([Fig. 1](#DEV142042F1){ref-type="fig"}Aa,d), whereas the inner plexiform layer (IPL) separating the GCL and NBL was significantly reduced (*P*\<0.05, [Fig. 1](#DEV142042F1){ref-type="fig"}Ad,e). Fig. 1.**Severe RGC loss in *Dlx1*/*Dlx2*^−/−^*Brn3b*^−/−^ retinas.** (A) There is a reduced GCL in mutant retinas. Compared with wild type (a), the GCL of the *Dlx1*/*Dlx2*^+/−^*Brn3b*^−/−^ single (b), *Dlx1*/*Dlx2*^−/−^*Brn3b*^+/−^ double (c) and *Dlx1*/*Dlx2*^−/−^*Brn3b*^−/−^ triple (d) KO retinas appear reduced, but no significant difference can be distinguished between the mutants. Near fusion of the GCL and NBL is evident in the TKO (inset in d, arrows) with significant reduction of the IPL (e). Insets show boxed regions at a higher magnification. Asterisk marks the optic nerve head. (Ba-h) Immunostaining with RGC markers BRN3A and ISL1 shows decreased RGCs in all mutant retinas at E18.5; the effect is more severe in the TKO (d; h, arrow). (i-l) Significant loss of ISL1+ RGC is observed only in TKO retinas at E13.5. (m,n) At E18.5, a more severe RGC loss is detected in the TKO (95% reduced BRN3A+ and 84% reduced ISL1+ cells). (o) At E13.5, 81% ISL1+ RGC loss occurs only in TKO retinas. Histograms represent the mean±s.d., *n*=4, \**P*\<0.01. L, lens; NBL, neuroblastic layer; R, retina. Scale bars: 50 μm in Ad, 25 μm in insets; 20 μm in Bh; 50 μm in Bl.

Few RGCs were detected in the TKO ([Fig. 1](#DEV142042F1){ref-type="fig"}Bd,h) with ∼95% reduction of BRN3A+ RGCs in the TKO (78.5±14) compared with wild type (2701±148) (*P*\<0.01, *n*=4) and ∼80% loss of ISL1+ cells in the TKO (*P*\<0.01, *n*=4) ([Fig. 1](#DEV142042F1){ref-type="fig"}Bm,n). Decreased BRN3A+ cells (37%) and ISL1+ cells (40%) were also observed in *Dlx1*/*Dlx2* DKO retinas ([Fig. 1](#DEV142042F1){ref-type="fig"}Bc,g,m,n). However, RGC loss in *Brn3b*-null retinas (64% of BRN3A+ cells, 56% of ISL1+ cells) at E18.5 ([Fig. 1](#DEV142042F1){ref-type="fig"}Bb,f,m,n) did not reach the 70% loss previously reported ([@DEV142042C19]; [@DEV142042C24], [@DEV142042C23]). At E16.5, both BRN3A+ and ISL1+ RGCs were diminished in *Brn3b* SKO, *Dlx1*/*Dlx2* DKO and TKO retinas. At E13.5, ISL1 was used to detect RGCs due to low BRN3A expression at this developmental time-point, with 82% reduction of ISL1+ expression, but only in the TKO (*P*\<0.01, *n*=4) ([Fig. 1](#DEV142042F1){ref-type="fig"}Bi-l,o). Similar reductions of ISL+ RGCs were observed in E12.5 TKO retinas ([Fig. S2](Fig. S2)). *Dlx1*/*Dlx2* and *Brn3b* may have redundant functions during early retinogenesis, as neither knockout mouse demonstrated defective early retinal differentiation.

Increased amacrine cells in the *Dlx1*/*Dlx2*/*Brn3b*-null ganglion cell layer {#s2b}
------------------------------------------------------------------------------

Amacrine, horizontal and cone cells all have overlapping birthdates with RGCs. PAX6+ cells located in the inner NBL were counted as amacrine cells. No significant difference in PAX6 expression was observed when comparing wild-type with the KO models ([Fig. 2](#DEV142042F2){ref-type="fig"}A-D,Q). PAX6 is expressed in both RGCs and in displaced amacrine cells in the GCL at E18.5 ([@DEV142042C5]; [@DEV142042C12]; [@DEV142042C28]). PAX6+ cells in the GCL of *Brn3b* SKO and *Dlx1/Dlx2* DKO were reduced in number ([Fig. 2](#DEV142042F2){ref-type="fig"}B,C) due to RGC loss ([@DEV142042C13]; [@DEV142042C23]). However, in the TKO GCL, there was only minimal reduction in the number of PAX6+ cells ([Fig. 2](#DEV142042F2){ref-type="fig"}D), supporting the observation of more displaced amacrine cells in the TKO GCL. Syntaxin is present in all amacrine cells but not in RGCs ([@DEV142042C4]). The number of TKO GCL cells was only partially reduced ([Fig. 2](#DEV142042F2){ref-type="fig"}H). A significant 1.8-fold increase of syntaxin+ cells was observed in the TKO GCL (1761±122) compared with wild type (930±72) (*P*\<0.01, *n*=4) ([Fig. 2](#DEV142042F2){ref-type="fig"}E-H,R). However, syntaxin+ cells in *Brn3b* SKO and *Dlx1/Dlx2* DKO GCL were not significantly altered. Fig. 2.**Increased number of amacrine cells are located in the *Dlx1*/*Dlx2*^−/−^*Brn3b*^−/−^ ganglion cell layer.** (A-D,Q) No significant differences in PAX6+ amacrine cells are identified in the inner NBL in the different mutants (arrows, Q). However, more PAX6+ cells are evident in the TKO GCL (D). (E-H,R) Syntaxin immunostaining reveals increased number of displaced amacrine cells in the TKO GCL (H, arrows), with a 1.8-fold increase in syntaxin+ amacrine cells (R). (I-L,S) The horizontal cell marker NF165 is expressed at expected levels (S) and in the expected position in the TKO (arrow). (M-P,T) Recoverin expression is not significantly different between the mutants and wild type. Data are mean±s.d., *n*=4, \**P*\<0.01. Scale bar: 20 μm.

No significant abnormalities in horizontal cell number or position were observed in TKO retinas ([Fig. 2](#DEV142042F2){ref-type="fig"}I-L,S). Most cone photoreceptors are born prenatally in mice, but many markers are not detected until P5 ([@DEV142042C10]). Recoverin is expressed by cones and cone bipolar cells from E17.5 ([@DEV142042C39]). No abnormalities in recoverin+ cell position ([Fig. 2](#DEV142042F2){ref-type="fig"}M-P) or number ([Fig. 2](#DEV142042F2){ref-type="fig"}T) were identified.

To determine the identity of displaced amacrine cells of TKO retinas, we cultured E18.5 TKO and wild-type retina explants for 7 days *in vitro* (DIV7). GABAergic and glycinergic cells represent almost 90% of amacrine cells ([@DEV142042C35]). Glutamic acid decarboxylase (GAD) isoforms, GAD65 and GAD67, were similarly expressed in the IPL and GCL of wild-type and TKO DIV7 retinas ([Fig. 3](#DEV142042F3){ref-type="fig"}A,B). Starburst cholinergic amacrine cells (expressing choline acetyltransferase, ChAT) are early born GABAergic amacrine cells ([@DEV142042C51]). Compared with wild-type littermates ([Fig. 3](#DEV142042F3){ref-type="fig"}E), more ChAT+ cells are observed in the TKO GCL (98.4±9.7 vs 59.5±3.4, *P*\<0.01, *n*=4) ([Fig. 3](#DEV142042F3){ref-type="fig"}F). However, there was no difference in the expression of the glycinergic amacrine cell marker glycine transporter (GlyT1) ([Fig. 3](#DEV142042F3){ref-type="fig"}G,H). Similarly, there was no difference in expression of the bHLH NEUROD1 across the four genotypes ([Fig. S3](Fig. S3)). Upregulation of ChAT but not GlyT1 in TKO retinas is consistent with increased early born amacrine cells. Fig. 3.**More cholinergic amacrine cells are located in the GCL of TKO retinal explants.** (A-D) At 7 DIV, GAD65 and GAD67 are highly expressed in the IPL, as well as in the GCL and inner INL of both wild-type and TKO retinas (A-D, arrowheads). (E,F) More ChAT-expressing cells are located in the TKO GCL than in wild-type retina (E,F, arrowheads). (G,H) GlyT1 expression is restricted to the INL of both wild-type and TKO retinas (G,H, arrowheads). Scale bar: 20 μm. Blue staining is DAPI.

Birth-dating experiments labeled RPC with a single BrdU pulse in pregnant animals at E12.5, E13.5 or E16.5. Most E12.5 and E13.5 birth-dated cells were located in the GCL, without differences in quantity or spatial expression between TKO and wild-type controls ([Fig. 4](#DEV142042F4){ref-type="fig"}A,B,E,F; data not shown). Few E16.5 birth-dated cells migrated to the GCL; most remain in the NBL ([Fig. 4](#DEV142042F4){ref-type="fig"}C,D,G,H). BrdU+ cell numbers in the GCL were similar in wild-type and TKO in the E12.5, E13.5 and E16.5 birth-dated retinas ([Fig. 4](#DEV142042F4){ref-type="fig"}I). Early migration of RPC to the GCL was unaffected in the TKO. Few cells were co-labeled by BRN3A and BrdU in E12.5 birth-dated TKO retinas (14±1 of mutants versus 199±10 of wild type, *P*\<0.005, *n*=4; [Fig. 4](#DEV142042F4){ref-type="fig"}A,B,J). However, more cells were co-labeled with syntaxin and BrdU in the GCL ([Fig. 4](#DEV142042F4){ref-type="fig"}E,F,K). Similar results were observed in E13.5, as well as in E16.5, birth-dated mutants ([Fig. 4](#DEV142042F4){ref-type="fig"}C,D,G,H,J,K; data not shown). Hence, in TKO retinas, most progenitors that exit mitosis migrate to the GCL and express amacrine rather than RGC markers (the proportion of RGC born at E12.5, E13.5 and E16.5 is shown in [Fig. S5](Fig. S5)). Fig. 4.**More retinal progenitors adopt an amacrine cell fate in the *Dlx1*/*Dlx2*^−/−^*Brn3b*^−/−^ mutant GCL.** (A,B,E,F) BrdU pulse labeling at E12.5 and co-expression with BRN3A or syntaxin reveal few RGCs in the TKO (A,B, arrows); more cells differentiate as amacrine cells and migrate to the GCL (E,F, arrows). Most E12.5 BrdU pulse-labeled cells are located in the GCL (B″,F″). (C,D,G,H) BrdU pulses at E16.5 identify more displaced amacrine cells in the TKO, although most BrdU+ cells remain in the NBL. Arrows in C and H mark BrdU+ cells that neither express BRN3A (C) nor syntaxin (H) in the GCL. (I-K) E12.5, E13.5 and E16.5 birth-dated cells identified similar quantities of BrdU+ cells in the GCL of wild-type and TKO retinas (I). At all stages tested, RPCs of the TKO adopt an amacrine rather than a RGC fate in the GCL (J,K). Data are mean±s.d., *n*=4, \**P*\<0.005, ^\#^*P*\<0.05. Scale bar: 20 μm.

Increased apoptosis and abnormal cell division in *Dlx1*/*Dlx2*/*Brn3b*-null retinas {#s2c}
------------------------------------------------------------------------------------

At E13.5, the TKO had a significant fourfold increase in apoptotic cells (70.5±11 of mutants versus 15.5±7 of wild type, *P*\<0.01, *n*=4; [Fig. 5](#DEV142042F5){ref-type="fig"}A,B,G). However, for E16.5 and E18.5 TKO, apoptotic cell numbers were similar to wild type ([Fig. 5](#DEV142042F5){ref-type="fig"}G). In the TKO at E13.5, the majority of caspase-3+ cells were confined to the inner retina, where prospective RGCs are located. Unlike the *Brn3b* SKO or *Dlx1*/*Dlx2* DKO, enhanced apoptosis later than E13.5 was not detected in the TKO. Fig. 5.**Combined loss of *Dlx1*/*Dlx2* and *Brn3b* results in enhanced apoptosis and abnormal cell proliferation.** (A,B,G) Cleaved caspase 3 immunostaining shows a fourfold increase in the number of apoptotic cells (arrows) in E13.5 TKO retinas (B,G). There is no significant difference in apoptosis at E16.5 and E18.5 (G). (C,D,H) Anti-phospho-histone H3 quantification revealed a decreased number of cells in M-phase at E16.5 and E18.5 in the TKO (D,H) but not at E13.5 (H). The boxed regions in C and D are shown at higher magnification beneath. (E,F,I) There are lower percentages of S-phase (*P*=0.005) and G2/M-phase (NS) cells at E16.5 in the TKO (*n*=3). Histograms represent the mean±s.d., *n*=4, \**P*\<0.01. Scale bars: 50 μm in B; 25 μm in D.

TKO retinas displayed a significant reduction (46% and 41%) in the number of M-phase cells at E16.5 ([Fig. 5](#DEV142042F5){ref-type="fig"}D,H) and E18.5, respectively ([Fig. 5](#DEV142042F5){ref-type="fig"}H). Similarly, fewer S-phase cells were detected in E16.5 and E18.5 mutants (data not shown). Flow cytometry yielded concordant results at E16.5 and E18.5, with significantly reduced proportions of cells in S phase (*P*=0.005, *n*=3) but changes in G2/M and G1/G0 phases were not significant ([Fig. 5](#DEV142042F5){ref-type="fig"}E,F,I; data not shown).

Expression of BRN3B and DLX2 in *Atoh7*-null retinas {#s2d}
----------------------------------------------------

*Atoh7*/*Dlx2* co-expressing cells are present at E11.5 when DLX2 is first detected ([Fig. 6](#DEV142042F6){ref-type="fig"}A-C), extending to E13.5 ([Fig. 6](#DEV142042F6){ref-type="fig"}D-F), but co-expression is absent at E18.5 ([Fig. 6](#DEV142042F6){ref-type="fig"}G-I, E16.5; J-K, E18.5). *Atoh7* expression was unaffected in the *Brn3b* SKO, *Dlx1/Dlx2* DKO and the TKO ([Fig. 7](#DEV142042F7){ref-type="fig"}A). BRN3B expression was severely reduced in the *Atoh7*^−/−^ retina at E13.5 ([Fig. 7](#DEV142042F7){ref-type="fig"}Bg,h) and E16.5 ([Fig. 7](#DEV142042F7){ref-type="fig"}Bi,j). However, DLX2 expression was significantly reduced at E13.5 (*P*=0.01, [Fig. 7](#DEV142042F7){ref-type="fig"}Ba,b,e) but not significantly in the *Atoh7*-null GCL at E16.5, a time when *Atoh7* expression is downregulated (*P*=0.09, [Fig. 7](#DEV142042F7){ref-type="fig"}Bc,d,f). Interestingly, of the few BRN3B+ cells remaining in the *Atoh7*^−/−^ GCL at E16.5, a proportion co-express DLX2 (data not shown), supporting a role for DLX2 in promoting or maintaining *Brn3b* expression in the absence of *Atoh7* function. Fig. 6.***Atoh7*** **mRNA and DLX2 protein are co-expressed at early but not late embryonic stages.** (A-C) *Atoh7* mRNA and DLX2 protein are expressed in the central E11.5 retina. (D-F) At E13.5, *Atoh7* mRNA is expressed throughout the retina, except the inner central region; *Atoh7*+/DLX2+ cells are located in the middle layer. *Atoh7*−/DLX2+ cells are easily detected in the inner central retina, where differentiated cells are located. *Atoh7*+/DLX2− cells are restricted to the outmost proliferating zone. (G-I) *Atoh7* expression is downregulated at E16.5 (G, arrowheads). DLX2 is strongly expressed in the GCL and inner NBL (H, arrows). Double-positive cells can be detected in the NBL (I, inset, arrows). (J-L) At E18.5, *Atoh7* is localized proximal to the ciliary margin (J, arrowheads). DLX2 expression is restricted in the GCL and inner NBL (K, arrows), without double-positive cells. Scale bars: 100 µm. Fig. 7.***Atoh*7** **expression is not affected by the combined deletion of *Dlx1*/*Dlx2* and *Brn3b*.** (A) *In situ* hybridization at E13.5 shows *Atoh7* expression throughout the proliferating zone of developing retina, except for the ciliary margin. No difference was detected between wild type and the genetic mutants. Scale bar: 40 μm. (B) DLX2 and BRN3B expression is downregulated in *Atoh7*-null retinas at E13.5. (a-f) DLX2 expression is significantly reduced in the *Atoh7* KO at E13.5 (a,b,e) but not at E16.5 (c,d,f). (G-J) BRN3B levels are severely reduced in the *Atoh7*^−/−^ retina at both E13.5 (g,h) and E16.5 (i,j).

DLX1/DLX2 regulate *Brn3b* by specific binding to the *Brn3b* promoter *in vivo* {#s2e}
--------------------------------------------------------------------------------

As development proceeds, more BRN3B-positive cells express DLX2 and, from E16.5, all BRN3B+ cells co-express DLX2 ([Fig. S1](Fig. S1)). We postulated that DLX1 and/or DLX2 regulate *Brn3b* transcription during retinogenesis. We used chromatin immunoprecipitation (ChIP) of embryonic retina and specific antibodies to detect DLX proteins localized to the *Brn3b* promoter region *in vivo.* Candidate regions were selected based on groups of putative TAAT/ATTA homeodomain consensus DNA-binding motifs. We focused on a region of the *Brn3b* promoter 2263 bp upstream of the start codon. ChIP was performed by using PFA crosslinked cells prepared from E16.5 retina with hindbrain used as a negative tissue control ([@DEV142042C57]). For PCR analysis, we designated seven fragments as 3bP1-3bP7. Only site 3bP4 was amplified from DLX1- or DLX2-immunoprecipitated DNA, confirming DLX1 and DLX2 occupancy of this *Brn3b* promoter region in E16.5 retina ([Fig. 8](#DEV142042F8){ref-type="fig"}Aa,b). Fig. 8.**DLX1 and DLX2 regulate *Brn3b* expression.** (A) DLX1 and DLX2 proteins bind to the *Brn3b* promoter region. (a) *Brn3b* has candidate homeodomain binding sites located within the 5′-promoter region (denoted 3bP4) (a, underlined). (b) ChIP identified specific *Brn3b* promoter DNA sequences occupied by DLX1/DLX2 *in vivo* (lanes 1, 2). E16.5 hindbrain was a negative tissue control. Control ChIP was performed without primary antibodies (lane 3). Genomic DNA was used as positive input (lane 4). (c) Using recombinant (r) DLX1 and DLX2 proteins, EMSA demonstrated direct and specific *in vitro* binding of DLX1/DLX2 proteins to the *Brn3b* promoter region (3bP4) identified by ChIP *in situ*. Radiolabeled 3bP4 oligonucleotides, when incubated alone, migrate as free probe (lanes 1, 6). rDLX1 or rDLX2 proteins form complexes with labeled 3bP4 probe and are shifted (lanes 2, 7 arrows, respectively). Specific DLX1/DLX2 antibodies, when incubated with rDLX1/rDLX2 proteins and labeled 3bP4 probe, form supershifted bands (lanes 4, 9 arrowheads, respectively). Excess unlabeled probe was used for cold competition (lanes 3, 8). An antibody to mouse IgG was used as a control without supershifts (lanes 5, 10). (B) DLX1/DLX2 activate *Brn3b* transcription *in vitro*. Co-transfection of either *Dlx1* or *Dlx2* with the *Brn3b* promoter region 3bP4 reporter construct activated luciferase activity. Mutations of any of the three candidate binding motifs significantly reduced the activation of reporter gene activity by DLX1 and DLX2. \**P*\<0.05, \*\**P*\<0.01. (C) Knockdown of *Dlx2* expression in primary embryonic retinal cultures at E14.5 results in decreased *Brn3b* expression. (a) RT-PCR shows reduced expression of *Dlx2* and *Brn3b* mRNA in the *Dlx2* siRNA transfected cells, compared with untreated and control siRNA transfected cells. (b,c) Quantitative real-time RT-PCR demonstrated efficient knockdown of *Dlx2* expression using specific siRNA but not with control siRNA. *Dlx2* knockdown results in a significant reduction in *Brn3b* expression (\**P*\<0.05).

Radiolabeled 3bP4 oligonucleotide fragments were incubated with recombinant DLX1/DLX2 proteins; we observed two specific protein-DNA band shifts as DLX1-3bP4 and DLX2-3bP4 complexes in electrophoretic mobility shift assays (EMSA) ([Fig. 8](#DEV142042F8){ref-type="fig"}Ac, lanes 2,7). These bands were competitively inhibited by unlabeled 3bP4 probe ([Fig. 8](#DEV142042F8){ref-type="fig"}Ac, lanes 3,8), and were 'supershifted' by addition of specific DLX1 or DLX2 antibodies ([Fig. 8](#DEV142042F8){ref-type="fig"}Ac, lanes 4,9). IgG was used as a control antibody ([Fig. 8](#DEV142042F8){ref-type="fig"}Ac, lanes 5,10).

We then performed transient co-transfection and site-directed mutagenesis assays. A plasmid expressing *Dlx1* or *Dlx2*, or both, was co-transfected into HEK293 cells with a vector in which the *Brn3b* 3bP4 promoter region drives reporter gene expression. DLX1 and DLX2 co-transfection resulted in 2.1- and 2.5-fold increases of luciferase activity, respectively ([Fig. 8](#DEV142042F8){ref-type="fig"}b). Co-transfection of *Dlx1* with *Dlx2* yielded similar results to *Dlx2* co-transfection alone ([Fig. S4](Fig. S4)). Mutations of any of the three candidate binding motifs within the 3bP4 promoter region significantly reduced luciferase activity by DLX1 and DLX2 *in vitro*, suggesting that DLX1- or DLX2-mediated activation of 3bP4 promoter expression may occur via any one of these binding sites.

*Brn3b* expression is decreased by *Dlx2* knockdown in primary embryonic retinal cultures {#s2f}
-----------------------------------------------------------------------------------------

Primary cultures of wild-type E14.5 retina were transiently transfected with siRNA targeting the *Dlx2*-coding sequence or a scrambled control siRNA ([@DEV142042C14]). There was efficient knockdown of *Dlx2* mRNA, with a concomitant decrease of *Brn3b* mRNA expression, compared with the transfection of control siRNA and untreated cells ([Fig. 8](#DEV142042F8){ref-type="fig"}c). Taken together with the RGC phenotype of the *Dlx1*/*Dlx2* DKO ([@DEV142042C13]), these knockdown experiments support that *Dlx2* function is necessary for *Brn3b* expression *in situ*.

Gain of *Dlx2* function *in utero* results in ectopic *Brn3b* expression *in vivo* {#s2g}
----------------------------------------------------------------------------------

Gain-of-function assays in retinal explants are compromised by the loss of trophic support of RGCs due to optic nerve transection during tissue preparation ([@DEV142042C14]). Subsequently, we ectopically expressed *Dlx2* in the intact embryo. E14.5 retinas were electroporated *in utero* with pCIG2-mCherry-*Dlx2* ([Fig. 9](#DEV142042F9){ref-type="fig"}A-G) or pCIG2-mCherry control plasmids ([Fig. 9](#DEV142042F9){ref-type="fig"}H-J) then harvested at E18. In pCIG2-mCherry-*Dlx2* electroporated retinas, mCherry epifluorescence reflects ectopic DLX2 expression in the outer NBL (arrows in [Fig. 9](#DEV142042F9){ref-type="fig"}C,D) with ectopic BRN3B expression in the outer NBL (arrows in [Fig. 9](#DEV142042F9){ref-type="fig"}F,G). Endogenous DLX2 and BRN3B expression was also detected in the GCL and INL (stars in [Fig. 9](#DEV142042F9){ref-type="fig"}C,D,F,G,I,J). No ectopic BRN3B was detected in the control NBL ([Fig. 9](#DEV142042F9){ref-type="fig"}I,J). Similar results were obtained from additional experimental (3) and control (2) electroporated retinas. To distinguish from endogenous DLX2 or BRN3B expression, cell counting was performed on mCherry+ cells located in the outer NBL but not in the GCL. Eighty-four percent of mCherry+ cells express DLX2 in *Dlx2* electroporated retinas. Twelve percent of these mCherry+ cells co-express BRN3B in *Dlx2* but not in control electroporated retinal patches *in vivo*. *P*\<0.01, *n*=4 ([Fig. 9](#DEV142042F9){ref-type="fig"}K). These *in utero* gain-of-function experiments support that exogenous *Dlx2* gene function is sufficient for *Brn3b* expression in the embryonic retina *in vivo*. Fig. 9.***In utero* electroporation of *Dlx2* results in ectopic *Brn3b* expression *in vivo*.** E14.5 retinas electroporated with pCIG2-mCherry-*Dlx2* (A-G) and pCIG2-mCherry control (H-J) plasmids were harvested at E18. In pCIG2-mCherry-*Dlx2* electroporated retinas, mCherry epifluorescence replicated ectopic DLX2 expression in the outer NBL (arrows in C,D), resulting in ectopic BRN3B expression in the outer NBL (arrows in F,G); results are quantified in K. Endogenous DLX2 and BRN3B expression was also detected in the GCL and INL (stars in C,D,F,G,I,J). No ectopic BRN3B expression was detected in control electroporated NBL (I,J). Scale bars: 50 μm in A; 20 μm in B-J.

Regulation of *Dlx2* expression by BRN3B is not mediated by direct interactions with *Dlx1*/*Dlx2* regulatory regions *in vivo* {#s2h}
-------------------------------------------------------------------------------------------------------------------------------

*Brn3b* negatively regulates *Dlx1* and *Dlx2* in the embryonic retina ([@DEV142042C41]; [@DEV142042C47]). We observed a transient increase in DLX2 expression at E13.5 but not at E11.5 or E16.5 in the *Brn3b* SKO retina ([Fig. S6](Fig. S6)). As RGC apoptosis occurs in *Brn3b* mutants at ∼E15.5, the initial increase in DLX2 expression could be lost due to the ensuing cell death. Repression of *Dlx2* by BRN3B could occur earlier, during the peak of early born RGC differentiation regulated by *Atoh7-Brn3b*. This repression is removed with diminishing *Atoh7* expression after E16.5 ([@DEV142042C6]).

We tested whether this negative regulation could be due to occupancy of *Dlx1*/*Dlx2* regulatory regions by BRN3B. *Cis*-acting elements of the *Dlx1*/*Dlx2* bigenic cluster include two intergenic enhancers, I12b and I12a, and two upstream regulatory elements (URE), URE1 and URE2 ([@DEV142042C25], [@DEV142042C26]) ([Fig. S7](Fig. S7)). These elements were examined for consensus *Pou*4f2 DNA-binding sites \[5′-(A/G)TTAATGAG(C/T)-3′\] ([@DEV142042C55]); two putative binding sites are in URE2 with one site in I12b. Two putative *Pou4f2*-binding sites were also found in *Dlx1* exon 3 and *Dlx2* exon 2. BRN3B directly regulates expression of *Eomes*, a T-box TF ([@DEV142042C36]). BRN3B occupancy was not detected at any of these four *Dlx1*/*Dlx2 cis*-regulatory regions, although we replicated binding to the *Eomes* promoter ([Fig. S7](Fig. S7)). Hence, repression of *Dlx1*/*Dlx2* expression by BRN3B is likely mediated by protein-protein interactions ([@DEV142042C22]) rather than transcriptional regulation.

DISCUSSION {#s3}
==========

Downstream of ATOH7, *Dlx1*/*Dlx2* and *Brn3b* are necessary for RGC specification {#s3a}
----------------------------------------------------------------------------------

Neither *Dlx1/Dlx2* nor *Brn3b* is necessary for the initiation of RGC differentiation. Expression of TFs positioned upstream of *Dlx1*/*Dlx2* or *Brn3b*, such as *Atoh7* and *Vsx2* (*Chx*10), is required for the competence of RPC to initiate expression of *Brn3b* and *Dlx1*/*Dlx2* for terminal differentiation, maturation and survival of RGCs ([@DEV142042C52]; [@DEV142042C56]). DLX1/DLX2 expression originates in *Chx10*+ cells ([@DEV142042C12]); similarly, using lineage tracing in the zebrafish retina, *Ath*5-expressing progenitors originate from Vsx2+ RPC ([@DEV142042C29]; [@DEV142042C50]).

The observed 70% loss of RGCs in *Brn3b* KO mice occurs at E15.5 or later, whereas 33% loss of RGCs in the *Dlx1*/*Dlx2* DKO mice is detected by E18.5 ([@DEV142042C13]; [@DEV142042C24]). Unlike these 'late' RGC losses, we found that the TKO resulted in a dramatic reduction of RGCs by E12.5. Although most E12.5 and E13.5 birth-dated retinal cells were in the GCL, few expressed RGC differentiation markers in the TKO. In addition to increased apoptosis in the TKO, decreased proliferation, as demonstrated by decreased staining for phospho-H3 (M-phase marker) and reduced S-phase (by FACS analysis), could also contribute to the observed dramatic RGC loss. Potentially, this cell cycle phenotype in the TKO could be due to increased expression of cell cycle regulators such as p53, CDKN1B (p27) or CDKN1C (p57). Hence, without affecting early migration of RPC to the nascent GCL, combined loss of *Dlx1*/*Dlx2* and *Brn3b* function severely impaired RGC genesis, proliferation, differentiation and survival.

In *Isl1*/*Brn3b* DKO mice, there was severe RGC loss but normal RGC genesis before E13.5, and with *Brn3b*, *Isl1* was shown to define a distinct, yet overlapping, RGC subpopulation under the regulation of ATOH7 ([@DEV142042C42]; [@DEV142042C45]). Almost complete RGC loss, as well as severe losses of other retinal cell types, resulted in *Atoh7*/*Brn3b* DKO mice ([@DEV142042C40]). Based upon co-expression of DLX2 with *Atoh7* or BRN3B as early as E11.5, reduced DLX2 expression in the *Atoh7* KO at E13.5 ([Fig. 7](#DEV142042F7){ref-type="fig"}) and report of a *Dlx* regulatory region as a direct ATH5 target in the chick retina ([@DEV142042C15]), we propose that *Atoh7-Brn3b/Isl1* and *Atoh7*-*Dlx1*/*Dlx2*-*Brn3b* regulate parallel transcriptional pathways for RGC differentiation ([Fig. 10](#DEV142042F10){ref-type="fig"}). *Atoh7* and *Dlx2* co-expressing RPCs could later co-express DLX2/BRN3B. Furthermore, downregulation of DLX2 by BRN3B in some RGC progenitors may be a mechanism underlying RGC subtype specification. Lineage tracing and evaluation of cadherin 6 ([@DEV142042C11]) and other markers will contribute towards identifying a role for specific RGC subtypes. Deletion of both *Isl1* and *Brn3b* would not affect RPC competence to become RGCs, as *Dlx1*/*Dlx2* would be available for promoting RGC differentiation. However, deletion of *Dlx1*/*Dlx2* and *Brn3b* would block two of the more dominant pathways for RGC differentiation and survival. The few remaining RGC in *Dlx1*/*Dlx2*/*Brn3b* compound mutants could derive from the small population of *Isl1*-expressing progenitors ([Fig. 1](#DEV142042F1){ref-type="fig"}Bh), which are distinct from those expressing *Brn3b* ([@DEV142042C40]), although ISL1 also co-labels ChAT+ amacrine cells. Interestingly, these early born cholinergic amacrine cells also derive from *Ath*5-lineage cells ([@DEV142042C30]). ISL1 and BRN3B can cooperate to specify RGC cell fate ([@DEV142042C33]; [@DEV142042C53]). Fig. 10.**A model for transcriptional regulation of RGC differentiation.** (A) Loss of DLX2-expressing cells in E13 *Atoh7* KO supports *Dlx1*/*Dlx2* participation in a regulatory pathway downstream of *Atoh7*, where, along with *Brn3b* and *Isl1*, *Dlx1*/*Dlx2* then co-regulates the genes required for RGC differentiation and survival. In addition, cross-regulation of these factors is observed. Loss of *Dlx2*, *Brn3b* or *Isl1* individually does not affect initial RGC genesis, suggesting that a combination/co-regulation of these factors and/or other unidentified factors are responsible for RGC fate specification. In later development, loss of *Dlx2*, *Brn3b* and *Isl1* all result in increased RGC death, supporting the requirement of these factors for RGC survival by controlling the expression of genes necessary for this process, including transcriptional control of *Brn3a* by DLX2 (Q.Z. and D.D.E., unpublished), ISL1 and BRN3B ([@DEV142042C45]), and DLX2-mediated regulation of *Trkb* ([@DEV142042C14]). Solid lines, established regulation; broken lines, proposed regulation. (B) *Atoh7* expression begins at ∼E11, preceding *Dlx1*/*Dlx2* and *Brn3b*. *Atoh7* and *Dlx1* expression are both downregulated after E16.5, with neither detected after P0. *Dlx2* and *Brn3b* expression starts at E11.5 and persists to adulthood.

In addition to early RGC loss, we found a significant increase in dislocated amacrine cells in the E18.5 TKO GCL. This result was unexpected, as only RGCs are affected by deletion of either *Dlx1*/*Dlx2* or *Brn3b* ([@DEV142042C13]; [@DEV142042C19]; [@DEV142042C23]). A similar phenotype was reported in *Atoh7* mutants, with increased cones, bipolar and Müller cells, and increased starburst amacrine cells in the GCL ([@DEV142042C7]; [@DEV142042C52]). *Atoh7*, which is expressed in RPC, promotes RGC specification by driving cell cycle exit and repressing non-RGC specifying TFs ([@DEV142042C6], [@DEV142042C7]; [@DEV142042C27]; [@DEV142042C30]; [@DEV142042C32]; [@DEV142042C42]). However, lineage tracing of *Atoh7*+ cells in the mouse also suggests a more indirect role for *Atoh7* in RGC specification ([@DEV142042C8]).

Amacrine cell specification in TKO retinas might result from a different mechanism than that found in the *Atoh7* mutants. There was preserved expression of *Atoh7* and NEUROD1 in the *Brn3b* KO, *Dlx1*/*Dlx2* KO and TKO mice. RPCs may accumulate more than one competency by expressing 'early' factors, such as *Atoh7* or *Neurod1*. Using lineage tracing, *Atoh7* expression is associated with RGC, photoreceptors, horizontal and amacrine cells ([@DEV142042C56]). Cells with restricted developmental potentials migrate properly and are further specified to differentiate under the regulation of factors expressed later in retinogenesis. In this case, both *Dlx1*/*Dlx2* and *Brn3b* could act downstream of *Atoh7*, promoting the terminal differentiation of RGCs ([Fig. 10](#DEV142042F10){ref-type="fig"}). Without *Dlx1*/*Dlx2* and *Brn3b*, cells restricted to RGC and amacrine cell fates migrate to the GCL but are unable to terminally differentiate into RGCs and either undergo apoptosis or differentiate into amacrine cells.

Interestingly, there is an increase in ISL+ cholinergic amacrine cells in a *Atoh7*-*Cre* knock-in mouse ([@DEV142042C21]). Similarly, the *Barhl2* KO retina demonstrates a twofold increase in ChAT+ amacrine cells and 35% RGC cell death ([@DEV142042C16]). A *Neurod1* knock-in at the *Atoh7* locus re-established RGC gene expression, specification and optic nerve formation, without over-producing amacrine cells ([@DEV142042C37]). RPC single cell gene-expression profiles showed significant levels of *Atoh7*, *Neurog2* and *Neurod1* in individual RPCs ([@DEV142042C48]). Hence, 'early' factors, including *Atoh7* and *Neurod1*, advance RPC to more narrowly defined but overlapping competencies, whereas, 'late' factors, such as *Dlx1*/*Dlx2* and *Brn3b*, promote these restricted-potential RPCs towards more specialized fates.

*Dlx1*/*Dlx2* and *Brn3b* function in co-regulatory genetic pathways {#s3b}
--------------------------------------------------------------------

Spatiotemporal DLX2 and BRN3B expression studies supported a second, later phase of *Brn3b* expression regulated by DLX1/DLX2. Both DLX1 and DLX2 bind to a specific *Brn3b* promoter region *in situ* and activate its expression *in vitro*. Knockdown of *Dlx2* in primary cultures resulted in decreased expression of *Brn3b*, consistent with reduced BRN3B expression in the *Dlx1*/*Dlx2* DKO ([@DEV142042C13]). Ectopic expression of BRN3B occurred following *in utero* retinal electroporation of *Dlx2*. These observations strongly support the direct regulation by DLX1 and DLX2 of *Brn3b* transcription *in vivo*. Hence, *Dlx1* and/or *Dlx2* are necessary and sufficient for *Brn3b* expression during retinal development.

Loss of *Dlx1*/*Dlx2* function results in reduced expression of *Pou3f1* and *Pou3f4* in the embryonic forebrain ([@DEV142042C2]), suggesting that DLX1/DLX2 could regulate other Class III POU HD TFs besides *Brn3b*, such as *Brn3a* or *Brn3c* (*Pou4f3*) in the developing retina and might further explain the severe retinal phenotype observed in the TKO. Loss of *Dlx1* and/or *Dlx2* function could reduce transcription of all *Brn3* genes in the retina, therefore blocking the functional redundancy of *Brn3* family members ([@DEV142042C44]).

Taken together, the mutual regulatory interactions between *Dlx1*/*Dlx2* and *Brn3b*, and the more severe phenotype observed in the TKO suggests that *Atoh7*-*Dlx1*/*Dlx2*-*Brn3b* and *Atoh7*-*Brn3b*/*Isl1* are two parallel but cross-regulatory genetic pathways in retinogenesis ([Fig. 10](#DEV142042F10){ref-type="fig"}). Characterization of the *Dlx1* and *Dlx2* transcriptomes will further contribute to understanding their role in retinal development.

MATERIALS AND METHODS {#s4}
=====================

Animal and tissue preparation {#s4a}
-----------------------------

Animal studies were carried out in accordance with guidelines established by the Canadian Council on Animal Care. *Dlx1/Dlx2* DKO mice were generated as previously described ([@DEV142042C1]; [@DEV142042C46]). *Brn3b* SKO mice (provided by W.H.K.) were maintained on a CD1 background. The *Dlx1/Dlx2*^+/−^ *Brn3b^+/−^* compound heterozygous line from crossing *Dlx1/Dlx2*^+/−^ heterozygotes with *Brn3b^+/−^* heterozygotes was used to generate *Dlx1/Dlx2/Brn3b* triple homozygous-null (TKO) mice. For comparative studies, all TKO mice were paired with *Dlx1/Dlx2*^+/−^*Brn3b^−/−^* (SKO), *Dlx1/Dlx2*^−/−^*Brn3b^+/−^* (DKO) and *Dlx1/Dlx2*^+/−^*Brn3b^+/−^* (all genetic heterozygotes are wild type) littermate controls. Genotyping was performed as previously described ([@DEV142042C23]; [@DEV142042C46]). Embryonic age was determined by the day of appearance of the vaginal plug (E0.5). E16.5 and E18.5 eyes were dissected from embryos whereas E13.5 eyes were left *in situ* prior to brief fixation in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS). Tissues were sectioned coronally at 12 μm.

Histology, immunofluorescence, TUNEL assay and *in situ* hybridization {#s4b}
----------------------------------------------------------------------

Histological and immunofluorescence staining on cryosections was performed as described previously ([@DEV142042C13]). Primary antibodies used were: mouse anti-BrdU (1:200, Chemicon), mouse anti-BRN3A (1:200, Santa Cruz), goat anti-BRN3B (1:200, Santa Cruz), rabbit anti-caspase 3 (1:500, Cell Signaling Technologies), rabbit anti-DLX2 (1:400, C199 affinity purified), mouse anti-ISLET1 (1:600, DSHB, University of Iowa), rabbit anti-phosphohistone H3 (1:1000, Upstate), rabbit anti-PROX1 (1:500, Chemicon), rabbit anti-PAX6 (1:800, Covance) and mouse anti-syntaxin (1:6000, Sigma). Secondary antibodies and fluorescent tertiary molecules used were: FITC-conjugated goat anti-rabbit (1:200), biotin-SP-conjugated goat anti-rabbit (1:200), biotin-SP-conjugated goat anti-mouse (1:200) (Jackson ImmunoResearch), streptavidin-conjugated Oregon Green 488 (1:200) and streptavidin-conjugated Texas Red (1:200) (Molecular Probes). Negative controls omitted the primary antibody. TUNEL staining used the In Situ Cell Death Detection Kit, TMR Red (Roche Diagnostics). Non-radioactive digoxigenin *in situ* RNA hybridization was performed as described previously ([@DEV142042C13]).

Retinal explant and amacrine subtype analysis {#s4c}
---------------------------------------------

Retinas were dissected from E18.5 TKO and wild-type littermates, and transferred onto Millicell-CM cell culture insert with 0.4 μm filters (Millipore). After removing the lens and the hyaloid vessels, retinas were flattened and cultured at 37°C with 5% CO~2~ in a humidified incubator. Explant culture media contained 50% high-glucose MEM, 25% Hank\'s solution, 25% horse serum, 200 μM L-glutamine, 6.75 mg/ml glucose, 2.5 mM HEPES buffer solution and 1% penicillin/streptomycin. After 7 DIV, explants were fixed in 4% PFA for 30 min and sectioned. ChAT+ cells were counted at 120 μm intervals and results were pooled.

Pulse labeling and birth-dating {#s4d}
-------------------------------

For pulse labeling, BrdU (100 μg/g) was injected intraperitoneally (i.p.) into pregnant dams 1 h before euthanasia. Sections were incubated in 50% formamide/2× SSC for 2 h at 65°C and 2 N HCl for 30 min at 37°C, followed by 0.1 M sodium borate for 10 min at room temperature.

Propidium iodide (PI) staining and cell cycle analysis {#s4e}
------------------------------------------------------

Retinas were dissociated into single cell suspensions in 1× PBS and fixed in 70% ethanol overnight at 4°C. Cells were resuspended in 250 μl propidium iodide (50 μg/ml) and 1 μl RNase (20 μg/ml), and incubated for 15 min at room temperature. Flow cytometry was performed on a FACSCalibur apparatus (Becton Dickinson), and analyzed using BD CellQuest Pro Version 3.5 software.

Cell counting and statistical analysis {#s4f}
--------------------------------------

Cell counts were performed on paired wild-type and mutant retinas ([@DEV142042C13]). For RGCs, BRN3A+ and ISL1+ cells located in the GCL were counted for E16.5 and E18.5 retinas; only ISL1 was used to count RGCs at E13.5. Only PAX6+ cells in the inner NBL were counted as amacrine cells; Syntaxin+/DAPI+ cells in the GCL were counted as dislocated amacrine cells; and PROX1+ cells located in the outer NBL were counted as horizontal cells. For BrdU birth-dating studies, the BRN3A+/BrdU+ cells represented RGCs born at the time of BrdU injection; syntaxin+/BrdU+ cells in GCL represent dislocated amacrine cells born at the time of the BrdU pulse. Statistical analyses were performed with SPSS software; the paired *t*-test was used; *P*\<0.05 was considered significant.

Microscopy and imaging {#s4g}
----------------------

Images were acquired using an Olympus BX51 microscope with a SPOT 1.3.0 digital camera (Diagnostic Instruments) or an Olympus DP70 digital camera. Fluorescent images were acquired using an Olympus IX81 inverted microscope with a Fluoview FV500 confocal laser scanning system (Olympus Optical). Images were processed using Adobe Photoshop software (Adobe Systems) for presentation.

Chromatin immunoprecipitation and electrophoretic mobility shift assays {#s4h}
-----------------------------------------------------------------------

E16.5 retina tissues were isolated for ChIP assays as described previously ([@DEV142042C57]). Oligonucleotide primers for PCR amplification were designed according to the *Brn3b* gene promoter sequence (MGI 102524). The primer sets were: S4F, 5′-GTTCAGCAGACTGTTGCCAC-3′ and S4R, 5′-TCCTTCCTCACTCAACACTGAG-3′. The target region (S4-pro) is 318 bp and located at position 81,326,124-81,326,442, on mouse chromosome 8, within the 5′ proximal promoter 2.6 kb upstream of the *Brn3b* transcription start site. Genomic DNA from the E16.5 mouse embryo tail was used as a positive control. PCR products were purified for TOPO TA cloning and sequenced. Oligonucleotide primers for ChIP experiments using embryonic retina and BRN3B antibody ([Fig. S7](Fig. S7)) are provided in the supplementary Materials and Methods.

For EMSA, the S4-pro region was excised from the pCR2.1-TOPO vector (Invitrogen) with *Eco*RI, and labeled with α-P^32^-dATP (PerkinElmer) using the Klenow (large) Fragment of DNA PolI (Invitrogen). The binding reaction mixture contained labeled probes (90,000 cpm), binding buffer \[20% glycerol, 5 mM MgCl~2~, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl and 50 mM Tris-HCl (pH7.5)\], 1 μg poly-dI-dC and purified recombinant DLX1 or DLX2 protein, and was incubated for 30 min at room temperature. A 100-fold excess of unlabeled probes was used for 'cold competition' experiments; rabbit polyclonal DLX1 and DLX2 antibodies were used for 'supershift' experiments; and a rabbit polyclonal antibody to mouse IgG (Jackson ImmunoResearch) was used as a negative antibody control.

Cell culture and reporter gene assays {#s4i}
-------------------------------------

HEK-293 cells were grown in alpha DMEM (Gibco) with 10% FBS at 37°C with 5% CO~2~. Twenty-four hours prior to transfection, cells were seeded at a density of 1×10^7^ per 36 mm^2^ dish. Lipofectamine 2000 reagent (Invitrogen) was used for transient transfection. Reporter plasmids were constructed by inserting the 318 bp S4-pro fragment into the pGL3-basic vector (Promega). Putative DLX DNA-binding sites in S4-pro were deleted, respectively, by site-directed mutagenesis using the Quick Change Kit (Stratagene); mutations (Δ1, Δ2 and Δ3) were verified by DNA sequencing. Effector plasmids expressing *Dlx1* and *Dlx2* genes were constructed by insertion of a PCR amplified 790 bp *Dlx1* cDNA and 1020 bp *Dlx2* cDNA (Dr J. Rubenstein, University of California at San Francisco, CA, USA) into the pcDNA3 vector (Invitrogen). The plasmid pRSV-β-gal (Promega) was co-transfected to assess transfection efficiency.

Primary embryonic retinal cell culture and siRNA transfection {#s4j}
-------------------------------------------------------------

E14.5 CD-1 mice retinas were dissociated with Accumax (Sigma-Aldrich) and cultured on poly-L-lysine and laminin-coated six-well plates. Cells were cultured in DMEM/F12 medium supplemented with HEPES, 0.1% BSA, 1% FBS, N2 and B27 (Invitrogen) at 37°C with 5% CO~2~ for 24 h before interfering RNA (siRNA) transfection. Two duplex siRNAs were designed to target the mouse *Dlx2*-coding sequence and a control siRNA was synthesized to scramble the *Dlx2*-coding sequence (Invitrogen). siRNAs were prepared and transfected as previously described ([@DEV142042C14]). RNA was isolated 48 h after transfection.

Real-time quantitative PCR analysis {#s4k}
-----------------------------------

RNA was extracted from cultured retinal cells with TRIzol (Invitrogen), and treated with DNase (Sigma). RNA (1 μg) was used to synthesize cDNA with SuperScript II reverse transcriptase (Invitrogen). cDNA (1 μl) was used as a template for gene amplification. Real-time quantitative PCR was performed using the iCycler iQ system (Bio-Rad). mRNA copy numbers were calculated using standard curves generated by using plasmids containing the target sequences. *Gapdh* was used to normalize *Dlx2* and *Brn3b* mRNA expression levels. Primers were: *Dlx2*-F, 5′ cca aac tca ggt caa aat ctg 3′; *Dlx2*-R, 5′ tta gaa aat cgt ccc cgc g 3′; *Brn3b*-F, 5′ gtc ggc agc ctc ctc ttc ttc tgt g; *Brn3b*-R, 5′ gct tct cgc ggt ggg att tct cag; *Gapdh*-F, 5′ ctc atg acc aca gtc cat gc 3′; *Gapdh*-R, 5′ cac att ggg ggg tag gaa cac 3′.

*In utero* electroporation {#s4l}
--------------------------

Timed pregnant C57/BL6 mice were used for *in utero* electroporation experiments. *Dlx2* cDNAs were cloned into pCIG2, an expression vector containing a CMV/β-actin enhancer/promoter and an IRES-mCherry cassette. Endotoxin-free plasmid DNA for electroporation was generated using a column-based purification system (Qiagen). *In utero* electroporation was performed as described previously ([@DEV142042C17]; [@DEV142042C31]; [@DEV142042C38]). Injection of E13.5 or E14.5 retinas took advantage of the pigmented retinal epithelium (RPE) for targeting; embryos developed until E18.5. Electroporated eyes were identified by mCherry epifluorescence.
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